Under construction – not a live service
Sign in
Taking people in ChinaPhase 2

Tests durvalumab with chemotherapy and radiation for limited-stage small-cell lung cancer

Tests durvalumab with chemotherapy and radiation in adults with limited-stage small-cell lung cancer.

Key facts

Who runs it
Qian Chu
Where
Wuhan and Zhengzhou, ChinaSee the 2 sites
Trial code
Registry title
Durvalumab as Consolidation for Patients LS-SCLC
Status
Recruiting
Phase
Phase 2
People taking part
100 people, planned
Started
24 Feb 2026
Expected to end
31 Jul 2029
Type of study
Interventional
Treatments tested
  • Induction Durvalumab +etoposide/platinum +Radiochemotherapy+ durvalumab maintenance
Record updated
27 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with limited-stage small-cell lung cancer who have not yet had chest radiotherapy or chemotherapy for it. They would get durvalumab with etoposide/platinum chemotherapy, then chemoradiotherapy, then durvalumab again.

Age
Older than 18 years
Sex
All sexes
Disease stage
Small-cell lung cancer confirmed by tissue or cell tests, limited stage (stage I-III, no spread to distant organs). People with stage I or II must be medically unable to have surgery. At least 1 tumor spot not treated with radiation before.
Earlier treatment
No earlier chest radiotherapy or chemotherapy for small-cell lung cancer. No earlier treatment in a durvalumab clinical study. No live weakened vaccine within 30 days before the first dose.

Main reasons for not taking part

  • Extensive-stage small-cell lung cancer
  • Earlier organ transplant from another person
  • Active or past autoimmune or inflammatory disease
  • Active hepatitis infection (some past or treated cases may join)
  • Cancer spread to the membranes around the brain and spinal cord (leptomeningeal carcinomatosis)

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • 1.Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
  • 2.Histologically or cytologically confirmed small cell lung cancer
  • 3.Limited-stage, defined as stage I-III SCLC (T any, N any, M0). Patients who are Stage I or II must be medically inoperable as determined by investigator
  • 4.Age > 18 years
  • 5.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • 6.Adequate normal organ and marrow function
  • 7.Must have a life expectancy of at least 12 week
  • 8.At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target lesion (TL) at baseline. Tumor assessment by computed tomography (CT) scan or magnetic resonance imaging (MRI) must be performed within 28 days prior to enrollment

Who cannot take part

  • 2.Patients who previously received radiotherapy to the thorax or chemotherapy for small cell lung cancer
  • 5.Any concurrent chemotherapy other than study treatment, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable
  • 7.Active or prior documented autoimmune or inflammatory disorders
  • 13.Receipt of live attenuated vaccine within 30 days prior to the first dose of IP
  • 14.Prior treatment in a previous durvalumab clinical study
  • 1.Patients with extensive disease small-cell lung cancer
  • 6.History of allogenic organ transplantation
  • 8.Uncontrolled intercurrent illness
  • 9.History of leptomeningeal carcinomatosis
  • 11.History of active primary immunodeficiency
  • 12.Known active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc), at screening. Participants with a past or resolved HBV infection (defined as the presence of antiHBc and absence of HBsAg) and with undetectable HBV DNA (< 10 IU/ml or under the limit of detection per local lab standard) are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA
  • 15.Known allergy or hypersensitivity to IP or any excipient
  • 3.Any previous diagnosis of transformed non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation positive NSCLC that has transformed to SCLC, or mixed SCLC NSCLC histology. Patients with mixed histology tumors with predominant SCLC histology are allowed
  • 4.Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values
  • 10.Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart)

Where in China

  • Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaContact: Qian Chu, Head of the Thoracic Cancer DeTaking people
  • The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer HospitalZhengzhou, ChinaContact: Huijuan WangTaking people

About the trial

What the trial wants to find out

Small-Cell Lung Cancer (SCLC) accounts for 10% to 15% of new lung cancers and is a highly aggressive neuroendocrine tumor. In the past 30 years, the treatment of SCLC has made very limited progress, and basically made breakthroughs in radiotherapy and chemotherapy. With the advent of the immune era, immunotherapy has achieved initial results in the treatment of SCLC. Approximately one-third of patients with small cell lung cancer are in limited-stage (LS-SCLC) disease at first diagnosis. Except for a very small number of patients with T1-2N0 who can be treated with surgery or stereotactic radiation therapy (SBRT), the standard treatment for the rest of the patients with LS-SCLC is concurrent chemoradiotherapy. The ORR of platinum-combined etoposide regimen combined with thoracic radiotherapy in LS-SCLC can reach 70% to 90%, and the median OS is 16-24 months, which significantly improves the survival of patients. Although many measures have been taken in the treatment of LS-SCLC, only 20% of LS-SCLC can be cured, and most patients have relapse and metastasis after treatment. This study is a single arm phase II preliminary pilot study, aim to assess the efficacy and safety of durvalumab combined with EP prior to CRT and followed by durvalumab consolidation therapy for LS-SCLC.

The group in the trial

  • single arm, multi-center, phase II studyTreatment being tested

    Treatment: Induction Durvalumab +etoposide/platinum +Radiochemotherapy+ durvalumab maintenance

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase II Study of Durvalumab Combined With EP Prior to Chemoradiotherapy and Followed by Durvalumab as Consolidation for Patients With Limited-stage Small-cell Lung Cancer (CONCUR Study)
Plain-language title
Tests durvalumab with chemotherapy and radiation for limited-stage small-cell lung cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
27 March 2026